Conventos em tempos de crise. O Convento do Espírito Santo da Pedreira de Lisboa. Quatro desenhos de projecto de José Joaquim Ludovice

Fundação para a Ciência e a Tecnologia (FCT), Fundação Millennium bcp

Palabra escrita y poder. La biblioteca del convento franciscano de Córdoba del Tucumán. (Siglos XVII Y XVIII).

El objeto de este proyecto es el estudio de la biblioteca del convento franciscano de Córdoba del Tucumán entre los siglos XVII y XVIII, a través de los únicos inventarios patrimoniales de sus libros, el primero redactado en 1726 y el segundo en 1815. La rareza y riqueza de la fuente hallada, muy poco común para la ciudad y otros espacios de Argentina, amerita el estudio de la circulación y posesión del libro, así como de la conformación de uno de los acervos coloniales bibliográficos más importantes de los entonces Tucumán, Paraguay y Río de la Plata, después de la Librería Grande del Colegio Máximo de la Compañía de Jesús de Córdoba.

Anàlisi i proposta de millora de la gestió del Memorial Auschwitz-Birkenau

La conservació d’un museu de les característiques del Memorial Museu Auschwitz-Birkenau és de vital importància. La realització d’aquest projecte pretén trobar les mancances que el museu pugui tenir per tal d’aportar-hi solucions. El museu té problemes per a conservar les seves instal·lacions a causa de la manca de fons econòmics i del gran nombre de visites que rep anualment

Iowa Centennial Memorial Foundation, May 31, 2003

State Agency Audit Report

Iowa Centennial Memorial Foundation, May 31, 2002

State Agency Audit Report

Iowa Centennial Memorial Foundation, Independent Auditor's Reports Financial Statements and Supplementary Information, May 31, 2004

State Agency Audit Report

Investigation of the State Insurance Division's Oversight of Clinton Memorial Cemetery & Funeral Home, Inc, 1999

Investigative report produced by Iowa Citizens' Aide/Ombudsman

Iowa Centennial Memorial Foundation, Independent Auditor's Reports, Financial Statements and Supplementary Information, May 31st, 2004

State Audit Reports

Memorial Union Revenue Bond Funds, Iowa State University of Science and Technology, Independent Auditor's Reports, Financial Statements, June 30, 2005

State University Audit Report

Iowa Centennial Memorial Foundation, Independent Auditor's Reports, Financial Statements and Supplementary Information, May 31, 2006

State Audit Reports

Memorial Union Revenue Bond Funds, Iowa State University of Science and Technology, Independent Auditor's Report, Basic Financial Statements and Supplementary Information, June 30, 2006

State University Audit Report

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

BACKGROUND: Uveal melanoma exhibits a high incidence of metastases; and, to date, there is no systemic therapy that clearly improves outcomes. The anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody ipilimumab is a standard of care for metastatic melanoma; however, the clinical activity of CTLA-4 inhibition in patients with metastatic uveal melanoma is poorly defined. METHODS: To assess ipilimumab in this setting, the authors performed a multicenter, retrospective analysis of 4 hospitals in the United States and Europe. Clinical characteristics, toxicities, and radiographic disease burden, as determined by central, blinded radiology review, were evaluated. RESULTS: Thirty-nine patients with uveal melanoma were identified, including 34 patients who received 3 mg/kg ipilimumab and 5 who received 10 mg/kg ipilimumab. Immune-related response criteria and modified World Health Organization criteria were used to assess the response rate (RR) and the combined response plus stable disease (SD) rate after 12 weeks, after 23 weeks, and overall (median follow-up, 50.4 weeks [12.6 months]). At week 12, the RR was 2.6%, and the response plus SD rate was 46.%; at week 23, the RR was 2.6%, and the response plus SD rate was 28.2%. There was 1 complete response and 1 late partial response (at 100 weeks after initial SD) for an immune-related RR of 5.1%. Immune-related adverse events were observed in 28 patients (71.8%) and included 7 (17.9%) grade 3 and 4 events. Immune-related adverse events were more frequent in patients who received 10 mg/kg ipilimumab than in those who received 3 mg/kg ipilimumab. The median overall survival from the first dose of ipilimumab was 9.6 months (95% confidence interval, 6.3-13.4 months; range, 1.6-41.6 months). Performance status, lactate dehydrogenase level, and an absolute lymphocyte count ≥ 1000 cells/μL at week 7 were associated significantly with survival. CONCLUSIONS: In this multicenter, retrospective analysis of 4 hospitals in the United States and Europe of patients with uveal melanoma, durable responses to ipilimumab and manageable toxicity were observed.